USD 23.15
(-1.53%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 651.93 Million USD | -16.62% |
2022 | 158.31 Million USD | -9.97% |
2021 | 814.98 Million USD | 167.4% |
2020 | 192.41 Million USD | -60.63% |
2019 | 786.3 Million USD | -6.84% |
2018 | 813.91 Million USD | 8.42% |
2017 | 750.69 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 141.19 Million USD | -333.09% |
2024 Q2 | 138.34 Million USD | -11.47% |
2024 Q3 | -277.38 Million USD | 45.07% |
2023 Q4 | 149.44 Million USD | 0.95% |
2023 FY | - USD | -16.62% |
2023 Q3 | 148.04 Million USD | 3.48% |
2023 Q2 | 143.06 Million USD | -7.65% |
2023 Q1 | 154.91 Million USD | 25.03% |
2022 Q3 | 141.47 Million USD | -29.3% |
2022 Q2 | 200.11 Million USD | -10.12% |
2022 Q1 | 222.63 Million USD | 4.84% |
2022 FY | - USD | -9.97% |
2022 Q4 | 123.9 Million USD | -12.42% |
2021 Q4 | 212.36 Million USD | 2.5% |
2021 Q3 | 207.19 Million USD | 6.95% |
2021 Q2 | 193.73 Million USD | 4.76% |
2021 Q1 | 184.92 Million USD | 188.2% |
2021 FY | - USD | 167.4% |
2020 Q1 | 187.97 Million USD | -6.14% |
2020 Q4 | -209.65 Million USD | -93.35% |
2020 Q3 | -108.43 Million USD | -189.38% |
2020 Q2 | 121.31 Million USD | -35.46% |
2020 FY | - USD | -60.63% |
2019 Q3 | 178.77 Million USD | -5.66% |
2019 Q1 | 189.5 Million USD | 0.0% |
2019 FY | - USD | -6.84% |
2019 Q4 | 200.27 Million USD | 12.03% |
2019 Q2 | 189.5 Million USD | 0.0% |
2018 FY | - USD | 8.42% |
2017 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
American Well Corporation | -225.99 Million USD | 388.478% |
Doximity, Inc. | 195.46 Million USD | -233.526% |
Evolent Health, Inc. | -24.78 Million USD | 2730.357% |
Phreesia, Inc. | -102.94 Million USD | 733.284% |
Teladoc Health, Inc. | 153.99 Million USD | -323.342% |
Veeva Systems Inc. | 429.33 Million USD | -51.848% |